Arash Mahajerin
YOU?
Author Swipe
View article: D.6 Changes in intravenous or subcutaneous immunoglobulin usage before and after efgartigimod initiation in patients with Myasthenia Gravis
D.6 Changes in intravenous or subcutaneous immunoglobulin usage before and after efgartigimod initiation in patients with Myasthenia Gravis Open
Background: While efgartigimod usage is expected to reduce immunoglobulin (IG) utilization, evidence in clinical practice is limited. Methods: In this retrospective cohort study, patients with gMG treated with efgartigimod for ≥1-year were…
View article: Clinical and treatment characteristics of infants and toddlers less than 2 years of age with hemophilia
Clinical and treatment characteristics of infants and toddlers less than 2 years of age with hemophilia Open
Infants and toddlers (ITs) with hemophilia have unique bleeding features. Factor prophylaxis has been shown to decrease the risk of intracranial hemorrhage (ICH), which supports recommendations to begin at a young age. Clinical and demogra…
View article: Atypical Hemolytic Uremic Syndrome Treated With Ravulizumab or Eculizumab: A Claims-Based Evaluation of Health Care Resource Utilization and Clinical Outcomes in the United States
Atypical Hemolytic Uremic Syndrome Treated With Ravulizumab or Eculizumab: A Claims-Based Evaluation of Health Care Resource Utilization and Clinical Outcomes in the United States Open
View article: Antithrombin Therapy: Current State and Future Outlook
Antithrombin Therapy: Current State and Future Outlook Open
Antithrombin (AT) is a natural anticoagulant pivotal in inactivating serine protease enzymes in the coagulation cascade, making it a potent inhibitor of blood clot formation. AT also possesses anti-inflammatory properties by influencing an…
View article: Current practices in pediatric hospital‐acquired thromboembolism: Survey of the Children's Hospital Acquired Thrombosis (CHAT) Consortium
Current practices in pediatric hospital‐acquired thromboembolism: Survey of the Children's Hospital Acquired Thrombosis (CHAT) Consortium Open
Practices among institutions are variable in regard to use of HA-VTE prophylaxis, risk assessment, or guideline implementation, highlighting the need for further research and a validated risk assessment model through groups like the CHAT C…
View article: Channeling effects in the prescription of new therapies: the case of emicizumab for hemophilia A
Channeling effects in the prescription of new therapies: the case of emicizumab for hemophilia A Open
Aim: To determine if emicizumab was channeled to clinically complex people with hemophilia A upon approval. Methods: Claims data (16 November 2017, through 31 December 2019) from US-based insurance databases were analyzed to compare the cl…
View article: Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism
Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism Open
ClinicalTrials.gov Identifier: NCT00687882.
View article: A New Risk Assessment Model for Hospital-Acquired Venous Thromboembolism in Critically Ill Children: A Report From the Children's Hospital-Acquired Thrombosis Consortium.
A New Risk Assessment Model for Hospital-Acquired Venous Thromboembolism in Critically Ill Children: A Report From the Children's Hospital-Acquired Thrombosis Consortium. Open
Using the multicenter Children's Hospital-Acquired Thrombosis registry, we identified five independent risk factors for hospital-acquired venous thromboembolism in critically ill children, deriving a new hospital-acquired venous thromboemb…
View article: Development of a Risk Model for Pediatric Hospital-Acquired Thrombosis: A Report from the Children's Hospital-Acquired Thrombosis Consortium
Development of a Risk Model for Pediatric Hospital-Acquired Thrombosis: A Report from the Children's Hospital-Acquired Thrombosis Consortium Open
View article: Model of Short- and Long-Term Outcomes of Emicizumab Prophylaxis Treatment for Persons with Hemophilia A
Model of Short- and Long-Term Outcomes of Emicizumab Prophylaxis Treatment for Persons with Hemophilia A Open
Funding for this study was provided by Genentech. Raimundo and Patel are employees of Genentech and own stock or stock options. Zhou, Han, Ji, Fang, Zhong, and Betts are employees of Analysis Group, which received consultancy fees from Gen…
View article: Comparative validation study of risk assessment models for pediatric hospital‐acquired venous thromboembolism
Comparative validation study of risk assessment models for pediatric hospital‐acquired venous thromboembolism Open
View article: Editorial: Pediatric Venous Thromboembolism
Editorial: Pediatric Venous Thromboembolism Open
EDITORIAL article Front. Pediatr., 27 September 2018Sec. Pediatric Immunology Volume 6 - 2018 | https://doi.org/10.3389/fped.2018.00269
View article: Epidemiology and Risk Assessment of Pediatric Venous Thromboembolism
Epidemiology and Risk Assessment of Pediatric Venous Thromboembolism Open
The incidence of diagnosed venous thromboembolism (VTE) has been increasing concurrent with advances in technology and medical care that enhance our ability to treat pediatric patients with critical illness or complex multiorgan system dys…
View article: Unrelated Hematopoietic Cell Transplantation in a Patient with Combined Immunodeficiency with Granulomatous Disease and Autoimmunity Secondary to RAG Deficiency
Unrelated Hematopoietic Cell Transplantation in a Patient with Combined Immunodeficiency with Granulomatous Disease and Autoimmunity Secondary to RAG Deficiency Open
View article: Hospital-associated venous thromboembolism in pediatrics: a systematic review and meta-analysis of risk factors and risk assessment models
Hospital-associated venous thromboembolism in pediatrics: a systematic review and meta-analysis of risk factors and risk assessment models Open
Hospital-associated venous thromboembolism, including deep vein thrombosis and pulmonary embolism, is increasing in pediatric centers. The objective of this work was to systematically review literature on pediatric hospital-acquired venous…
View article: Successful Treatment of Secondary Graft Failure Following Unrelated Cord Blood Transplant with Hematopoietic Growth Factors in a Patient with Fanconi Anemia
Successful Treatment of Secondary Graft Failure Following Unrelated Cord Blood Transplant with Hematopoietic Growth Factors in a Patient with Fanconi Anemia Open
Graft failure following unrelated cord blood transplantation (UCBT) in patients with Fanconi anemia is associated with significant mortality. Second transplantation may be considered; however, the limited toxicity profile of hematopoietic …